Showing results (41-50 of 97) with videos related to

Sort By:
Pageof 10
BMC Cancer|April 5, 2019
CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trialFrançoise Rothé, Marion Maetens, Ghizlane Rouas, et al.
Breast Cancer Research : BCR|July 30, 2008
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signaturesPratyaksha Wirapati, Christos Sotiriou, Susanne Kunkel, et al.
Cancer Metastasis Reviews|November 7, 2012
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trialsFrançois-Clément Bidard, Tanja Fehm, Michail Ignatiadis, et al.
Cancer|July 9, 2026
Circulating tumor DNA in early breast cancer: Evidence, challenges, next stepsSerena Di Cosimo, Valentina Appierto, Carolina Reduzzi, et al.
NPJ Breast Cancer|November 13, 2025
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021Alexandra Thomas, Anthony Rhoads, Erica L Mayer, et al.
Endocrine-Related Cancer|May 15, 2014
Biology of breast cancer during pregnancy using genomic profilingHatem A Azim, Sylvain Brohée, Fedro A Peccatori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2024
Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast CancerAlexandra Thomas, Erica L Mayer, Angela DeMichele, et al.
Journal of the National Cancer Institute|November 1, 2017
Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor StatusMatteo Lambertini, Niels Kroman, Lieveke Ameye, et al.
Endocrine-Related Cancer|October 11, 2011
Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancerPhilippe L Bedard, Sandeep K Singhal, Michail Ignatiadis, et al.
BMC Genomics|November 22, 2014
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technologyDebora Fumagalli, Alexis Blanchet-Cohen, David Brown, et al.
Pageof 10